key: cord-0810389-sw48iegh authors: Ivashchenko, A. A.; Dmitriev, K. A.; Vostokova, N. V.; Azarova, V. N.; Blinow, A. A.; Egorova, A. N.; Gordeev, I. G.; Ilin, A. P.; Karapetian, R. N.; Kravchenko, D. V.; Lomakin, N. V.; Merkulova, E. A.; Papazova, N. A.; Pavlikova, E. P.; Savchuk, N. P.; Simakina, E. N.; Sitdekov, T. A.; Smolyarchuk, E. A.; Tikhomolova, E. G.; Yakubova, E. V.; Ivachtchenko, A. V. title: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19 date: 2020-08-04 journal: nan DOI: 10.1101/2020.07.26.20154724 sha: 041faf88e7e39c88383ea6db6defd73ce2d67cf0 doc_id: 810389 cord_uid: sw48iegh In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. The pandemic of the novel coronavirus infection (COVID-19) represents an unprecedented disaster for healthcare providers and economy worldwide. The urgent requirement for the effective treatments has sparked an intense effort on the part of the pharmaceutical industry and shifted drug development to a new scale of commitment and collaboration. On May 29, 2020 the Russian Ministry of Health (MoH) granted fast-track marketing authorization to AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. The drug was developed and brought to market within a period of only two months, a feat made possible by the highly concerted and coordinated efforts of regulator, industry, and health professionals. The marketing authorization makes AVIFAVIR the only oral drug approved for treatment of moderate to severe COVID-19 to date. Favipiravir is an RNA-dependent RNA polymerase inhibitor marketed in Japan (Avigan) [1] and China (Favilavir) as a second-line treatment of novel or re-emerging influenza outbreaks. Earlier this year it was reported to demonstrate antiviral activity against SARS-CoV-2 in Vero . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 4, 2020. The objective of the pilot stage of the clinical study was to conduct a preliminary assessment of the efficacy and safety of AVIFAVIR, and to select the optimal dosing regimen for further evaluation in moderately ill SARS-CoV-2 virus-infected patients at the pivotal stage. The study design was based on WHO R&D Blueprint recommendations for clinical trials of therapeutics for COVID-19 [5] . Upon signing the informed consent form and screening, 60 eligible patients with pneumonia associated with PCR confirmed COVID-19 were randomized at a 1:1:1 ratio to receive either AVIFAVIR 1600 mg BID on Day 1 followed by 600 mg BID on Days 2-14 (1600/600 mg), or AVIFAVIR 1800 mg BID on Day 1 followed by 800 mg BID on Days 2-14 (1800/800 mg), or SOC. Each treatment group comprised 20 patients and all randomized patients constituted safety and intent-to-treat (ITT) analysis sets. In the 40 AVIFAVIR-treated patients, the drug was administered for a mean period of 11 days, with antibiotics (30%) and anticoagulants (35%) as concomitant medications for COVID-19. SOC was assigned in the control group according to the recommended treatment schemes presented in the Russian MoH interim guidelines for treatment of COVID-19 [6] . Patients . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.26.20154724 doi: medRxiv preprint The study assessments included daily vital signs, SpO The primary efficacy endpoint at the pilot stage was the elimination of SARS-CoV-2 by Day 10 (defined as two negative PCR tests with at least a 24-hour interval). The "go-no-go" decision to start Phase III was based on the exact single-stage Phase II assessment at one-sided α =0.05 and 80% power [7] . Thirteen or more responders out of 18 treated patients would have been sufficient to demonstrate that the effect of the viral clearance in 80% of patients by Day 10 is plausible, and that the efficacy is greater than the presumably non-effective level of 50%. On Adverse drug reactions to AVIFAVIR were reported in 17.5% of patients (7/40) including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels (ALT and AST). The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 5.0% of patients (2/40). During the pilot stage of the study, 2 patients on AVIFAVIR 1600/600 mg were moved to ICU and received mechanical ventilation, 1 of them died due to deterioration of the disease. Both patients had concurrent chronic conditions that increased the risk of severe disease. By the time of the interim analysis 80.0% of patients (32/40) from the AVIFAVIR group and 90.0% of patients (18/20) from the SOC group were discharged from hospital after improvement in their condition. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 4, 2020. 62.5% of AVIFAVIR-treated patients (25/40) achieved viral clearance within 4 days after initiation of therapy, which was significantly higher than in the SOC group (p=0.018). There were no new safety concerns related to AVIFAVIR as all adverse reactions were mild to moderate in severity and were consistent with those reported previously for AVIGAN [1, 8] . Dose-dependent efficacy pattern was identified and will be studied further. The results of the pivotal stage of the study are expected in July 2020. The fast-track marketing authorization granted by the Russian MoH makes AVIFAVIR the only approved oral drug for treatment of moderate to severe COVID-19 to date. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 4, 2020. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.26.20154724 doi: medRxiv preprint Report on the Deliberation Results. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. Ministry of Health, Labour and Welfare Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (2020) WHO R&D Blueprint COVID 19 Experimental Treatments. COVID Classification of treatment types WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis Interim guidelines. Prevention, diagnostics and treatment of a new coronavirus infection (COVID-19), MOH of the Russian Federation Sample size tables for exact single-stage phase II designs the author/funder, who has granted medRxiv a license to display the preprint in perpetuity The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.26.20154724 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.26.20154724 doi: medRxiv preprint